{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T07:48:55Z","timestamp":1721548135979},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Ministry of Science and ICT of the Republic of Korea","award":["50330-2019, 50477-2019, 50541-2019"],"award-info":[{"award-number":["50330-2019, 50477-2019, 50541-2019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s12149-019-01401-5","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T01:42:33Z","timestamp":1569894153000},"page":"881-890","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparisons of 131I-rituximab treatment responses in patients with aggressive lymphoma and indolent lymphoma"],"prefix":"10.1007","volume":"33","author":[{"given":"Inki","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Hyun","family":"Byun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilhan","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Woon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyeong Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Yeop","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Moo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"issue":"1","key":"1401_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1401_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00259-016-3560-9","volume":"44","author":"CG England","year":"2017","unstructured":"England CG, Rui L, Cai W. Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies. Eur J Nucl Med Mol Imaging. 2017;44(3):517\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1401_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-13150-4_1","volume":"165","author":"BC Chiu","year":"2015","unstructured":"Chiu BC, Hou N. Epidemiology and etiology of non-hodgkin lymphoma. Cancer Treat Res. 2015;165:1\u201325.","journal-title":"Cancer Treat Res"},{"issue":"47","key":"1401_CR4","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359\u201368.","journal-title":"Oncogene"},{"issue":"8","key":"1401_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2217\/imt-2017-0169","volume":"10","author":"M Eskian","year":"2018","unstructured":"Eskian M, Khorasanizadeh M, Zinzani PL, Rezaei N. Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma. Immunotherapy. 2018;10(8):699\u2013711.","journal-title":"Immunotherapy"},{"issue":"1","key":"1401_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2010-02-269753","volume":"117","author":"MF Leahy","year":"2011","unstructured":"Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood. 2011;117(1):45\u201352.","journal-title":"Blood"},{"issue":"2","key":"1401_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1743-7563.2011.01393.x","volume":"7","author":"HJ Kang","year":"2011","unstructured":"Kang HJ, Lee SS, Kim KM, Choi TH, Cheon GJ, Kim WS, et al. Radioimmunotherapy with 131I-rituximab for patients with relapsed\/refractory B-cell non-Hodgkin's lymphoma (NHL). Asia Pac J Clin Oncol. 2011;7(2):136\u201345.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"4","key":"1401_CR8","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00280-013-2087-z","volume":"71","author":"HJ Kang","year":"2013","unstructured":"Kang HJ, Lee SS, Byun BH, Kim KM, Lim I, Choi CW, et al. Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2013;71(4):945\u201353.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1401_CR9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.critrevonc.2016.10.005","volume":"107","author":"M Eskian","year":"2016","unstructured":"Eskian M, Khorasanizadeh M, Kraeber-Bodere F, Rezaei N. Radioimmunotherapy in non-Hodgkin lymphoma: prediction and assessment of response. Crit Rev Oncol Hematol. 2016;107:182\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"1401_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1401_CR11","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","volume":"103","author":"LI Gordon","year":"2004","unstructured":"Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1\/2 study. Blood. 2004;103(12):4429\u201331.","journal-title":"Blood"},{"issue":"4","key":"1401_CR12","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","volume":"96","author":"MS Kaminski","year":"2000","unstructured":"Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96(4):1259\u201366.","journal-title":"Blood"},{"issue":"27","key":"1401_CR13","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1200\/JCO.2005.05.3470","volume":"24","author":"MF Leahy","year":"2006","unstructured":"Leahy MF, Seymour JF, Hicks RJ, Turner JH. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol. 2006;24(27):4418\u201325.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1401_CR14","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1093\/annonc\/mdi272","volume":"16","author":"NG Mikhaeel","year":"2005","unstructured":"Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16(9):1514\u201323.","journal-title":"Ann Oncol"},{"key":"1401_CR15","first-page":"368947","volume":"2014","author":"M Takahashi","year":"2014","unstructured":"Takahashi M, Momose T, Koyama K, Ichikawa M, Kurokawa M, Ohtomo K. Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy. Sci World J. 2014;2014:368947.","journal-title":"Sci World J"},{"issue":"4 Suppl","key":"1401_CR16","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/cncr.10304","volume":"94","author":"GL DeNardo","year":"2002","unstructured":"DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer. 2002;94(4 Suppl):1332\u2013488.","journal-title":"Cancer"},{"issue":"23","key":"1401_CR17","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1200\/JCO.2009.27.7863","volume":"28","author":"F Morschhauser","year":"2010","unstructured":"Morschhauser F, Kraeber-Bod\u00e9r\u00e9 F, Wegener WA, Harousseau J-L, Petillon M-O, Huglo D, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I\/II study in non-Hodgkin's lymphoma. J Clin Oncol. 2010;28(23):3709\u201316.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1401_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.2013.50.3110","volume":"32","author":"TM Illidge","year":"2014","unstructured":"Illidge TM, Mayes S, Pettengell R, Bates AT, Bayne M, Radford JA, et al. Fractionated 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF\/BNLI criteria. J Clin Oncol. 2014;32(3):212\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1401_CR19","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1182\/blood-2008-08-175653","volume":"113","author":"TM Illidge","year":"2009","unstructured":"Illidge TM, Bayne M, Brown NS, Chilton S, Cragg MS, Glennie MJ, et al. Phase 1\/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood. 2009;113(7):1412\u201321.","journal-title":"Blood"},{"issue":"1","key":"1401_CR20","first-page":"13","volume":"36","author":"A Mart\u00ednez","year":"2017","unstructured":"Mart\u00ednez A, Mart\u00ednez-Ramirez M, Mart\u00ednez-Caballero D, Beneit P, Clavel J, Figueroa G, et al. Radioimmunotherapy for non-Hodgkin's lymphoma: positioning, safety, and efficacy of 90Y-ibritumomab 10 years of experience and follow-up. Rev Esp Med Nucl Imagen Mol. 2017;36(1):13\u20139.","journal-title":"Rev Esp Med Nucl Imagen Mol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-019-01401-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-019-01401-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-019-01401-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T23:32:37Z","timestamp":1601335957000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-019-01401-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1401"],"URL":"https:\/\/doi.org\/10.1007\/s12149-019-01401-5","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,30]]},"assertion":[{"value":"17 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}